Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaWyndham H. Wilson, Louis M. Staudt, Darrin M. Beaupre et al.|Nature Medicine|2015Cited by 1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J. Nastoupil, Frederick L. Locke, Michael D. Jain et al.|Journal of Clinical Oncology|2020Cited by 782
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic modelCraig H. Moskowitz, Joachim Yahalom, Stephen D. Nimer et al.|Blood|2001Cited by 427
Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's LymphomaCraig H. Moskowitz, Andrew D. Zelenetz, Joseph R. Bertino et al.|Journal of Clinical Oncology|1999Cited by 303
Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphomaEunice S. Wang, Ariela Noy, David J. Straus et al.|Cancer|2003Cited by 151